Literature DB >> 17080030

Innovative lead discovery strategies for tropical diseases.

Solomon Nwaka1, Alan Hudson.   

Abstract

Lead discovery is currently a key bottleneck in the pipeline for much-needed novel drugs for tropical diseases such as malaria, tuberculosis, African sleeping sickness, leishmaniasis and Chagas disease. Here, we discuss the different approaches to lead discovery for tropical diseases and emphasize a coordination strategy that involves highly integrated partnerships and networks between scientists in academic institutions and industry in both wealthy industrialized countries and disease-endemic countries. This strategy offers the promise of reducing the inherently high attrition rate of the early stages of discovery research, thereby increasing the chances of success and enhancing cost-effectiveness.

Entities:  

Mesh:

Year:  2006        PMID: 17080030     DOI: 10.1038/nrd2144

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


  165 in total

1.  Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.

Authors:  Denise da Gama Jaén Batista; Marcos Meuser Batista; Gabriel Melo de Oliveira; Patrícia Borges do Amaral; Joseli Lannes-Vieira; Constança Carvalho Britto; Angela Junqueira; Marli Maria Lima; Alvaro José Romanha; Policarpo Ademar Sales Junior; Chad E Stephens; David W Boykin; Maria de Nazaré Correia Soeiro
Journal:  Antimicrob Agents Chemother       Date:  2010-05-10       Impact factor: 5.191

2.  Activity of the histone deacetylase inhibitor FR235222 on Toxoplasma gondii: inhibition of stage conversion of the parasite cyst form and study of new derivative compounds.

Authors:  Danièle Maubon; Alexandre Bougdour; Yung-Sing Wong; Marie-Pierre Brenier-Pinchart; Aurélie Curt; Mohamed-Ali Hakimi; Hervé Pelloux
Journal:  Antimicrob Agents Chemother       Date:  2010-08-16       Impact factor: 5.191

3.  Molecular docking and molecular dynamics study on SmHDAC1 to identify potential lead compounds against Schistosomiasis.

Authors:  Raghvendra Singh; Paras Nath Pandey
Journal:  Mol Biol Rep       Date:  2015-02-07       Impact factor: 2.316

Review 4.  Target assessment for antiparasitic drug discovery.

Authors:  Julie A Frearson; Paul G Wyatt; Ian H Gilbert; Alan H Fairlamb
Journal:  Trends Parasitol       Date:  2007-10-24

Review 5.  Drug discovery for malaria: a very challenging and timely endeavor.

Authors:  Michael H Gelb
Journal:  Curr Opin Chem Biol       Date:  2007-08       Impact factor: 8.822

6.  More medicines for neglected and emerging infectious diseases.

Authors:  Jack Radisch
Journal:  Bull World Health Organ       Date:  2007-08       Impact factor: 9.408

Review 7.  The challenges of developing novel antiparasitic drugs.

Authors:  Debra J Woods; Tracey M Williams
Journal:  Invert Neurosci       Date:  2007-11-15

Review 8.  Kinetoplastids: related protozoan pathogens, different diseases.

Authors:  Ken Stuart; Reto Brun; Simon Croft; Alan Fairlamb; Ricardo E Gürtler; Jim McKerrow; Steve Reed; Rick Tarleton
Journal:  J Clin Invest       Date:  2008-04       Impact factor: 14.808

9.  A novel Leishmania major amastigote assay in 96-well format for rapid drug screening and its use for discovery and evaluation of a new class of leishmanicidal quinolinium salts.

Authors:  Gerhard Bringmann; Katja Thomale; Sebastian Bischof; Christoph Schneider; Martina Schultheis; Tobias Schwarz; Heidrun Moll; Uta Schurigt
Journal:  Antimicrob Agents Chemother       Date:  2013-04-15       Impact factor: 5.191

10.  A Novel Sterol Isolated from a Plant Used by Mayan Traditional Healers Is Effective in Treatment of Visceral Leishmaniasis Caused by Leishmania donovani.

Authors:  Gaurav Gupta; Kevin J Peine; Dalia Abdelhamid; Heidi Snider; Andrew B Shelton; Latha Rao; Sainath R Kotha; Andrew C Huntsman; Sanjay Varikuti; Steve Oghumu; C Benjamin Naman; Li Pan; Narasimham L Parinandi; Tracy L Papenfuss; A Douglas Kinghorn; Eric M Bachelder; Kristy M Ainslie; James R Fuchs; Abhay R Satoskar
Journal:  ACS Infect Dis       Date:  2015-09-21       Impact factor: 5.084

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.